Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01826864

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Randomized Phase III Trial to Compare the Immunodulatory Effects of Leukine vs. Saline for Early-stage Melanoma Patients Undergoing Sentinel Lymph Node Dissection

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Jonsson Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients with melanoma. Biological therapies, such as sargramostim, may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether sargramostim is more effective than hypertonic saline in treating patients with stage IB-II melanoma undergoing sentinel lymph node biopsy.

Detailed description

PRIMARY OBJECTIVES: I. To determine if the alterations in morphology and phenotype to the sentinel lymph nodes are reversible. II. To determine if the restoration of the morphology or phenotype of sentinel lymph nodes results in diminished regional tumor burden. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive sargramostim subcutaneously (SC) 3-5 days prior to undergoing sentinel lymph node biopsy. ARM II: Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy. After completion of study treatment, patients are followed up for 30 days.

Conditions

Interventions

TypeNameDescription
BIOLOGICALsargramostimGiven SC
PROCEDUREsentinel lymph node biopsyUndergo sentinel lymph node biopsy
OTHERlaboratory biomarker analysisCorrelative studies
OTHERhypertonic salineGiven SC

Timeline

Start date
2011-08-05
Primary completion
2017-08-08
Completion
2017-08-08
First posted
2013-04-09
Last updated
2020-07-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01826864. Inclusion in this directory is not an endorsement.